drugset
drugset / Trial / NCT00906698

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

NCT00906698 ↗

Phase 1 Completed 55 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the maximum tolerated dose, safety, pharmacokinetics and anti-tumour efficacy of oral BIBW 2992 in combination with intravenous or oral vinorelbine

Timeline

Start
2009-06
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 20 mg Oral
Subject Afatinib Small molecule 40 mg Oral
Subject Afatinib Small molecule 50 mg Oral
Subject Vinorelbine Small molecule 25 mg/m2 Oral
Subject Vinorelbine Small molecule 80 mg/m2 Oral

Indications

neoplasm